Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Metabolism ; 65(11): 1636-1645, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27733252

ABSTRACT

BACKGROUND: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the primary omega-3 fatty acids in fish oil, have been shown to reduce cardiovascular disease (CVD) risk. OBJECTIVE: This study aimed to examine the independent effects of EPA and DHA on lipid and apolipoprotein levels, as well as on inflammatory biomarkers of CVD risk, using doses often used in the general population. DESIGN: A blinded, randomized 6-week trial was performed in 121 healthy, normolipidemic subjects who received olive oil placebo 6g/d, EPA 600mg/d, EPA 1800mg/d, or DHA 600mg/d. The EPA was derived from genetically modified yeast. RESULTS: The subjects tolerated the supplements well with no safety issues; and the expected treatment-specific increases in plasma EPA and DHA levels were observed. Compared to placebo, the DHA group had significant decreases in postprandial triglyceride (TG) concentrations (-20%, -52.2mg/dL, P=0.03), significant increases in fasting and postprandial low-density lipoprotein cholesterol (LDL-C) (+18.4%, 17.1mg/dL, P=0.001), with no significant changes in inflammatory biomarkers. No significant effects were observed in the EPA 600mg/d group. The high-dose EPA group had significant decreases in lipoprotein-associated phospholipase A2 concentrations (Lp-PLA2) (-14.1%, -21.4ng/mL, P=0.003). CONCLUSIONS: The beneficial effects of EPA 1800mg/d on CVD risk reduction may relate in part to the lowering of Lp-PLA2 without adversely affecting LDL-C. In contrast, DHA decreased postprandial TG, but raised LDL-C. Our observations indicate that these dietary fatty acids have divergent effects on cardiovascular risk markers.


Subject(s)
Cardiotonic Agents/pharmacology , Cardiovascular Diseases/epidemiology , Docosahexaenoic Acids/pharmacology , Eicosapentaenoic Acid/pharmacology , Apolipoproteins/blood , Apolipoproteins B/blood , Biomarkers/blood , Cholesterol, LDL/blood , Double-Blind Method , Female , Humans , Lipids/blood , Male , Middle Aged , Olive Oil/pharmacology , Phospholipases A2/blood , Risk Factors , Treatment Outcome , Triglycerides/blood
2.
Endocr Relat Cancer ; 23(9): R393-409, 2016 09.
Article in English | MEDLINE | ID: mdl-27552970

ABSTRACT

Ghrelin is a hormone with multiple physiologic functions, including promotion of growth hormone release, stimulation of appetite and regulation of energy homeostasis. Treatment with ghrelin/ghrelin-receptor agonists is a prospective therapy for disease-related cachexia and malnutrition. In vitro studies have shown high expression of ghrelin in cancer tissue, although its role including its impact in cancer risk and progression has not been established. We performed a systematic literature review to identify peer-reviewed human or animal in vivo original research studies of ghrelin, ghrelin-receptor agonists, or ghrelin genetic variants and the risk, presence, or growth of cancer using structured searches in PubMed database as well as secondary searches of article reference lists, additional reviews and meta-analyses. Overall, 45 (73.8%) of the 61 studies reviewed, including all 11 involving exogenous ghrelin/ghrelin-receptor agonist treatment, reported either a null (no statistically significant difference) or inverse association of ghrelin/ghrelin-receptor agonists or ghrelin genetic variants with cancer risk, presence or growth; 10 (16.7%) studies reported positive associations; and 6 (10.0%) reported both negative or null and positive associations. Differences in serum ghrelin levels in cancer cases vs controls (typically lower) were reported for some but not all cancers. The majority of in vivo studies showed a null or inverse association of ghrelin with risk and progression of most cancers, suggesting that ghrelin/ghrelin-receptor agonist treatment may have a favorable safety profile to use for cancer cachexia. Additional large-scale prospective clinical trials as well as basic bioscientific research are warranted to further evaluate the safety and benefits of ghrelin treatment in patients with cancer.


Subject(s)
Ghrelin , Neoplasms , Receptors, Ghrelin/agonists , Animals , Ghrelin/analogs & derivatives , Ghrelin/blood , Ghrelin/genetics , Ghrelin/therapeutic use , Humans , Neoplasms/blood , Neoplasms/drug therapy , Neoplasms/genetics
3.
J Clin Lipidol ; 6(6): 596-600, 2012.
Article in English | MEDLINE | ID: mdl-23312056

ABSTRACT

A female presented in infancy with hypotonia, undetectable serum glucose, lactic acidosis, and triglycerides >5000 mg/dL. The diagnosis of type 1A glycogen storage disease was made via the result of a liver biopsy, which showed increased glycogen and absent glucose-6-phosphatase enzyme activity. The patient was treated with dextrose administered orally, which was replaced by frequent feedings of cornstarch, which resulted in an improvement of her metabolic parameters. At age 18 years of age, she had marked hypertriglyceridemia (3860 mg/dL) and eruptive xanthomas and was treated with fenofibrate, atorvastatin, and fish oil. At age 29 years she was noted to have multiple liver adenomas, severe anemia, and hyperuricemia. Aggressive cornstarch therapy was commenced with a goal of maintaining her blood glucose levels >75 mg/dL and lactate levels <2 mmol/L. After 15 months on this regimen, her lipids levels (measured in mg/dL) off all medications were as follows: total cholesterol 222, triglycerides 179, high-density lipoprotein cholesterol 32, and calculated low-density lipoprotein cholesterol 154. Her weight was stable with a body mass index of 24.8 kg/m(2). Her liver adenomas had decreased in size, and her anemia and hyperuricemia had improved. She was homozygous for the R83C missense mutation in G6PC. Our data indicate that optimized metabolic control to maintain blood glucose levels >75 mg/dL is critical in the management of this disease.


Subject(s)
Glucose/metabolism , Glycogen Storage Disease Type I/metabolism , Lactic Acid/metabolism , Triglycerides/metabolism , Uric Acid/metabolism , Adenoma/diet therapy , Adenoma/pathology , Adolescent , Adult , Biomarkers/metabolism , Blood Glucose , Cholesterol, LDL/metabolism , Citric Acid Cycle , Female , Glycogen Storage Disease Type I/diet therapy , Glycogen Storage Disease Type I/pathology , Humans , Hypoglycemia/diet therapy , Hypoglycemia/pathology , Infant , Liver/diagnostic imaging , Liver/enzymology , Liver/pathology , Magnetic Resonance Imaging , Radiography , Starch/administration & dosage , Starch/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...